We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





YHLO Offers Series of SARS-CoV-2 Antigen Test Products to Meet Demand for Global COVID-19 Mass Screening

By HospiMedica International staff writers
Posted on 29 Jan 2021
Shenzhen YHLO Biotech Co., Ltd. More...
(Shenzhen, China) is offering a series of SARS-CoV-2 antigen test products to meet the growing demand for global COVID-19 mass screening.

As the COVID-19 global pandemic continues to increase in severity, the demand for mass screening continues to grow, making SARS-CoV-2 antigen tests an ideal option. Despite their relatively limited sensitivity, the significant specificity of COVID-19 antigen tests reported (99.5%) enables quick decisions regarding patient management. The reliable test results provided by SARS-CoV-2 antigen tests allow for timely identification of COVID-19 positive individuals. Unlike PCR assays, antigen tests offer several point-of-care advantages that make large-scale screening possible with minimal clinical laboratory and technician support.

In addition to diagnosis, COVID-19 antigen tests also allow for monitoring the clinical condition of diagnosed patients. Antigen tests can distinguish between the early and late phases of COVID-19, as the level of viral antigens has an inverse relationship with the progress of the disease. The information provided by antigen tests about a patient’s current infectious status is helpful in making clinical interpretations for the management of COVID-19 infected inpatients (differentiated isolation, ward transfer, discharge, etc.).

To assist in the efforts to combat the global pandemic, YHLO has launched iFlash-2019-nCoV Antigen Assay, GLINE-2019-nCoV Antigen Assay and UNICELL-2019-nCoV Ag Test, all of which are officially CE marked for international sales. These antigen assays are superior due to several features. For instance, YHLO’s iFlash-2019-nCoV Antigen Assay offers reliable results due to its high sensitivity and specificity, and has a high throughput of up to 300 tests per hour. In addition, its automated workflow reduces manual operation and prevents cross-infection for operators.

Similarly, YHLO’s GLINE-2019-nCoV Antigen Assay is completely electronic equipment-free, requires minimal operations, supports nasal/nasopharyngeal swab and delivers results within 15 minutes. YHLO’s affordable UNICELL-2019-nCoV Ag Test requires minimal laboratory operations and delivers time-saving results within 15 minutes in addition to offering the advantages of compact size for easy transportation & storage and traceable results for up to 5,000 result memories.




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.